Ameriprise
SPRO icon

Ameriprise’s Spero Therapeutics SPRO Stock Holding History

Ameriprise’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-402,963
Closed -$592K – 3951
2023
Q4 		$592K Sell
402,963
-60,678
-13% -$72.3K ﹤0.01% 3384
2023
Q3 		$561K Sell
463,641
-4,319
-0.9% -$5.98K ﹤0.01% 3363
2023
Q2 		$679K Buy
+467,960
New +$801K ﹤0.01% 3324
2022
Q2 		– Sell
-586,642
Closed -$5.1M – 3990
2022
Q1 		$5.1M Buy
586,642
+223,108
+61% +$2.29M ﹤0.01% 2413
2021
Q4 		$5.82M Sell
363,534
-13,561
-4% -$215K ﹤0.01% 2366
2021
Q3 		$6.94M Sell
377,095
-61,742
-14% -$991K ﹤0.01% 2150
2021
Q2 		$6.13M Buy
438,837
+4,049
+0.9% +$56.6K ﹤0.01% 2304
2021
Q1 		$6.4M Buy
434,788
+169,347
+64% +$2.98M ﹤0.01% 2235
2020
Q4 		$5.15M Buy
+265,441
New +$4.14M ﹤0.01% 2253
2020
Q3 		– Sell
-21,454
Closed -$290K – 3780
2020
Q2 		$290K Buy
+21,454
New +$241K ﹤0.01% 3375

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's SPRO Position: Q1 2024 in Review

Ameriprise sold out of Spero Therapeutics (SPRO) in Q1 2024, closing a stake of 402,963 shares — an estimated $592K sold.

Ameriprise first reported a position in SPRO in Q2 2020 and held it in 10 quarters. The position peaked at $6.94M in Q3 2021. 54 funds tracked by Wall St. Rank hold SPRO as of Q1 2024.

  • Ameriprise reported no remaining Spero Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 402,963 Spero Therapeutics shares in Q1 2024, an estimated $592K.
  • Ameriprise first reported a position in Spero Therapeutics in Q2 2020 and held it in 10 quarters.
  • Ameriprise's Spero Therapeutics position peaked at $6.94M in Q3 2021.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.